+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 12Years +
All Genders
ID06822426

Evaluating DefenCath Versus Heparin for Preventing Bloodstream Infections in Adults and Adolescents Receiving Total Parenteral Nutrition Through a Central Venous Catheter

Led by CorMedix Therapeutics · Updated on 2026-09-25

200

Participants Needed

24

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are conducting a Phase 3, randomized, double-blind, controlled study to evaluate the safety and effectiveness of DefenCath compared to heparin in preventing central line-associated bloodstream infections CLABSIs. The study includes adults and adolescents who receive home total parenteral nutrition TPN through a central venous catheter CVC. The trial aims to reduce the risk of bloodstream infections in this population by comparing two catheter lock solutions. Participants will be randomly assigned to receive either DefenCath or heparin as a catheter lock solution used for their central venous catheter. The treatments will be administered regularly as part of their ongoing TPN care, and the study will last up to 12 months. Both groups will be monitored under the same conditions to assess differences in infection rates and safety outcomes. During the study, participants or their caregivers will self-administer the catheter lock solution according to their usual TPN and line access schedule. They will also maintain a daily diary to record treatment adherence and any adverse events. Researchers will track the occurrence of bloodstream infections, safety events, laboratory results, vital signs, and physical exam findings throughout the 12-month period. This allows a comprehensive evaluation of both efficacy and safety over an extended time.

CONDITIONS

Brief Title

Comparing The Safety And Efficacy Of DEFENCATH® In Reducing Central-Line Bloodstream Infections (CLABSIs) In Adults And Adolescent Participants Receiving Total Parenteral Nutrition Through A Central Venous Catheter (CVC)

Research Team

L

Liz Hurlburt, Chief Clinical Strategy & Operations Officer

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here